2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 909

Smoking Behavior Changes after Rheumatoid Arthritis Diagnosis and Risk of Mortality during 36 Years of Prospective Follow-up
Abstract Number: 910

Tumor Necrosis Factor-Alpha Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
Abstract Number: 911

Patients with Rheumatoid Arthritis Are at Increased Risk of Both Ischemic and Non-Ischemic Heart Failure
Abstract Number: 912

Secondary Preventive Pharmacotherapy and Longterm Outcomes Following Acute Coronary Events in Patients with Prevalent Rheumatoid Arthritis
Abstract Number: 913

A Comparison of Physician Based and Patient Based Criteria for the Diagnosis of Fibromyalgia
Abstract Number: 914

When Fibromyalgia Criteria Misclassify
Abstract Number: 915

Defining Pain for Fibromyalgia Criteria: Multi-Site or Widespread? an Analysis of Data from Four UK Population-Based Studies
Abstract Number: 916

Assessing Alternative Selection Criteria for Fibromyalgia Patients within a Multicenter Chronic Pain Claims Database
Abstract Number: 917

Chronic Widespread Pain in Adolescents Is Highly Associated to Stress and Anxiety
Abstract Number: 918

Assessment of the Temporal Variation of the Fibromyalgia Patient Profile Between 2005 and 2013: Do Guidelines Inform Clinical Care?
Abstract Number: 919

Automated Case Identification of Lupus from an Electronic Health Record Using Novel Informatics Approaches
Abstract Number: 920

Patient Preferences for the Development of a Mobile Health (mHealth) Application (App) for Systemic Lupus Erythematosus (SLE) Patients: A Qualitative Study
Abstract Number: 921

Poverty Associated with Increase in Damage in SLE over Two-Year Period
Abstract Number: 922

Factors Associated with Performance on Quality Measures Pertaining to Assessment of Disease Activity in Juvenile Idiopathic Arthritis
Abstract Number: 923

Perceptions of Infectious Risk of Immunosuppressive Medications Among Treating Physicians

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].